Last week at the BIO International Convention, Ipsen SA’s chief business officer Philippe Lopes-Fernandes told Scrip the French group would continue its recent run of deals and a few days later it inked one worth potentially up to $1.2bn.
Ipsen Dealmaking Heats Up With Marengo Cold Tumor Collaboration
The France-based mid-sized drugmaker has solidified its pipeline through several external pacts in the past few years and its dealmaking is showing no signs of slowing down.
More from Strategy
More from Business
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
• By
A decision from the FDA is due by 28 September.